Antibodies for Effector Cell Redirection
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (20 December 2021) | Viewed by 8639
Special Issue Editors
Interests: antibody engineering; antibody-based immunotherapy; immune effector cell recruitment; bispecific antibodies; cancer immunotherapy
Interests: antibody hit discovery; antibody engineering; protein engineering; bispecific antibodies; monoclonal antibodies; single domain antibodies; immune cell redirection; immunoligands; antagonistic antibodies; agonistic antibodies; immune checkpoint inhibitors; phage display; yeast surface display; mammalian display; B cell selection strategies
Special Issue Information
Dear Colleagues,
Since the advent of cancer immunotherapy, the field of effector cell-redirecting agents/antibody derivatives has made tremendous progress. Consequently, multiple bispecific antibody derivates that harness the body’s own immune effector cell repertoire are currently being investigated in clinical trials. While traditionally, α/β T cells were the preferred effector cell population for redirection, today, multiple different types of effector cells are being exploited, including (but not limited to) NK cells, γ/δ T cells, macrophages, and neutrophils. Moreover, combinatorial approaches are known to date, involving several different immune cell populations that can be addressed in a direct manner (e.g., by addressing activating receptors or co-stimulatory signals shared by different cell populations) or via secondary effects (such as targeted cytokine release). In addition to triggering activating receptors on effector cells in a tumor-targeted fashion, we understand immune cell redirection in a broader manner, such as conditional blockade of inhibitory receptors or providing co-stimulatory signals within the tumor microenvironment. Beyond bi- and multispecific approaches, the choice of the antibody isotype and Fc engineering in general drastically impact the type of activated effector cell population and hence can be considered as additional aspects of immune cell redirection.
This Special Issue is dedicated to effector cell redirection in its entirety. We invite you to contribute with an original article or a review.
Prof. Dr. Matthias Peipp
Dr. Stefan Zielonka
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Antibody engineering
- Bispecific antibodies
- Multispecific antibodies
- Protein engineering
- Immunoligands
- Antibody Isotypes
- Fc engineering
- NK cells
- T cells
- Macrophages
- Dendridic cells
- Immune cell engagers
- Effector cell engagers
